Scholar Rock Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity

 

• Promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patients
• Objective response rate (ORR) of 21.4% and disease control rate of 57%
• Biomarker data supports proof of mechanism across multiple tumor types
• Combination therapy of SRK-181 and pembrolizumab was generally well tolerated
• Company to discuss SRK-181 program during conference call on third quarter 2023 financial results and business updates, Tuesday, November 7^th at 8 a.m. EST

https://www.biospace.com/article/releases/scholar-rock-presents-new-data-from-phase-1-dragon-trial-showing-promising-anti-tumor-activity-in-anti-pd-1-resistant-metastatic-ccrcc-patients-and-supporting-srk-181-continued-tolerability/